查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2031081

全球癌症生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Cancer Biomarker Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球癌症生物標記市場預計將從2025年的437.5億美元成長至2034年的1,320.6億美元，並預計在2026年至2034年間以13.06%的複合年成長率成長。該市場快速擴張的原因在於人們對癌症早期檢測、診斷和個人化治療的需求日益成長。癌症生物標記是能夠指示癌症存在或進展的生物分子，從而實現更準確、更及時的干涉。全球癌症負擔的加重以及對精準醫療的日益重視是推動市場成長的主要因素。醫療系統正擴大採用基於生物標記的診斷方法來改善患者的治療效果。

關鍵促進因素包括分子生物學的進步、腫瘤學研究投入的增加、診斷技術的進步。生物標記被廣泛用於篩檢、預後和治療監測，從而提高癌症治療的有效性。基因組學和蛋白​​質組學的整合有助於識別新的生物標記物，進一步擴展其應用範圍。此外，伴隨診斷的日益普及也推動了市場成長。

展望未來，由於生物標記發現和檢驗領域的持續創新，市場展現出強勁的成長潛力。諸如液態生物檢體等非侵入性診斷方法的開發將提高檢測的可及性和患者的舒適度。在新興市場，隨著醫療基礎設施的改善，預計這些方法的應用將會擴大。隨著精準腫瘤學的不斷發展，癌症生物標記市場預計將持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭動態以及主要參與者所採取的策略。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球癌症生物標記市場：依生物分子類型分類

  • 市場分析、洞察與預測
  • 蛋白質
  • 基因生物標記

第5章 全球癌症生物標記市場：依癌症類型分類

  • 市場分析、洞察與預測
  • 結腸癌
  • 肺癌
  • 攝護腺癌
  • 乳癌
  • 胃癌
  • 咽癌
  • 其他

第6章 全球癌症生物標記市場：按應用分類

  • 市場分析、洞察與預測
  • 個人化醫療/矯正醫療
  • 診斷
  • 新藥研發

第7章 全球癌症生物標記市場：依技術分類

  • 市場分析、洞察與預測
  • 生物資訊學和細胞遺傳學
  • 影像
  • 體學
  • 其他

第8章 全球癌症生物標記市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 亞太其他地區
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Laboratories
    • Biomerieux
    • Thermo Fisher Scientific
    • Quest Diagnostics
    • Dickinson And Company
    • Roche Diagnostics
    • Agilent Technologies
    • Illumina
    • Qiagen
    • Affymetrix Inc
簡介目錄
Product Code: VMR112117141

The global cancer biomarker market size is expected to reach USD 132.06 Billion in 2034 from USD 43.75 Billion in 2025, growing at a CAGR of 13.06 during 2026-2034.This market is advancing rapidly due to the increasing need for early detection, diagnosis, and personalized treatment of cancer. Cancer biomarkers are biological molecules that indicate the presence or progression of cancer, enabling more accurate and timely interventions. The rising global burden of cancer and the growing emphasis on precision medicine are significantly contributing to market growth. Healthcare systems are increasingly adopting biomarker-based diagnostics to improve patient outcomes.

Key drivers include advancements in molecular biology, increasing investment in oncology research, and the expansion of diagnostic technologies. Biomarkers are widely used in screening, prognosis, and treatment monitoring, enhancing the effectiveness of cancer therapies. The integration of genomics and proteomics is enabling the identification of new biomarkers, further expanding their application. Additionally, the growing adoption of companion diagnostics is supporting market expansion.

Future prospects indicate strong growth potential, with continuous innovation in biomarker discovery and validation. The development of non-invasive diagnostic methods, such as liquid biopsies, will enhance accessibility and patient comfort. Emerging markets are expected to witness increased adoption due to improving healthcare infrastructure. As precision oncology continues to evolve, the cancer biomarker market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Biomolecule Type

  • Protein
  • Genetic Biomarkers

By Cancer Type

  • Colorectal Cancer
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Stomach Cancer
  • Throat Cancer
  • Others

By Application

  • Personalized/Modified Medicine
  • Diagnosis
  • Novel Drug Research and Development

By Technology

  • Bioinformatics and Cytogenetics
  • Imaging
  • Omics
  • Others

COMPANIES PROFILED

  • Abbott Laboratories, Biomerieux, Thermo Fisher Scientific, Quest Diagnostics, Dickinson and Company, Roche Diagnostics, Agilent Technologies, Illumina, Qiagen, Affymetrix Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOMARKER MARKET: BY BIOMOLECULE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Biomolecule Type
  • 4.2. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOMARKER MARKET: BY CANCER TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Cancer Type
  • 5.2. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Throat Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOMARKER MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Personalized/Modified Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Novel Drug Research and Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOMARKER MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Technology
  • 7.2. Bioinformatics and Cytogenetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Omics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER BIOMARKER MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Biomolecule Type
    • 8.2.2 By Cancer Type
    • 8.2.3 By Application
    • 8.2.4 By Technology
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Biomolecule Type
    • 8.3.2 By Cancer Type
    • 8.3.3 By Application
    • 8.3.4 By Technology
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Biomolecule Type
    • 8.4.2 By Cancer Type
    • 8.4.3 By Application
    • 8.4.4 By Technology
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Biomolecule Type
    • 8.5.2 By Cancer Type
    • 8.5.3 By Application
    • 8.5.4 By Technology
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Biomolecule Type
    • 8.6.2 By Cancer Type
    • 8.6.3 By Application
    • 8.6.4 By Technology
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CANCER BIOMARKER INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Abbott Laboratories
    • 10.2.2 Biomerieux
    • 10.2.3 Thermo Fisher Scientific
    • 10.2.4 Quest Diagnostics
    • 10.2.5 Dickinson And Company
    • 10.2.6 Roche Diagnostics
    • 10.2.7 Agilent Technologies
    • 10.2.8 Illumina
    • 10.2.9 Qiagen
    • 10.2.10 Affymetrix Inc